You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-CD38

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Multiple Myeloma Trial in Orange, Sacramento, Oklahoma City (STI-1492)

Recruiting
  • Multiple Myeloma
  • STI-1492
  • Orange, California
  • +2 more
Jan 12, 2023

Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • STI-6129
  • Beijing, Beijing, China
  • +3 more
Jan 9, 2023

Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
Jan 17, 2023

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Multiple Myeloma Trial in Canton (STI-6129)

Recruiting
  • Multiple Myeloma
  • STI-6129
  • Canton, Ohio
    Gabrail Cancer Center
Jun 29, 2022

Multiple Myeloma Trial in France, United Kingdom (CID-103)

Recruiting
  • Multiple Myeloma
  • Nantes, France
  • +3 more
Apr 21, 2022

Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Recruiting
  • Plasma Cell Myeloma
  • Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 27, 2022

Relapsed or Refractory Multiple Myeloma Trial in United States (CAR2 Anti-CD38 A2 CAR-T Cells)

Completed
  • Relapsed or Refractory Multiple Myeloma
  • CAR2 Anti-CD38 A2 CAR-T Cells
  • Jacksonville, Florida
  • +3 more
Mar 14, 2022

Membranous Nephropathy Trial in Bergamo, Ranica (MOR202)

Recruiting
  • Membranous Nephropathy
  • Bergamo, BG, Italy
  • +1 more
Mar 4, 2022

Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma (MM)
  • 3x10(6) CART-38 cellls
  • +5 more
  • (no location specified)
Jul 15, 2022

AL Amyloidosis Trial in Scottsdale, Jacksonville, Rochester (procedure, biological, other)

Not yet recruiting
  • AL Amyloidosis
  • Bone Marrow Biopsy
  • +4 more
  • Scottsdale, Arizona
  • +2 more
Jun 2, 2023

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Actinium Ac 225-DOTA-Daratumumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis Trial in Duarte (biological, drug, procedure, other)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • +2 more
  • Daratumumab
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Multiple Myeloma Trial (Elranatamab (PF-06863135))

Temporarily not available
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • (no location specified)
Jul 15, 2022

Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Tumor Trial in Houston (procedure,

Active, not recruiting
  • Bladder Urothelial Carcinoma
  • +4 more
  • Biopsy
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

MMRR Treated With Belantamab Mafotidine on Monotherapy

Not yet recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • (no location specified)
May 23, 2022

Multiple Myeloma Trial in Nanjing (HLX15, US-sourced DARZALEX®, CN-sourced DARZALEX® -)

Not yet recruiting
  • Multiple Myeloma
  • Nanjing, Jiangsu, China
    Sir Run Run Hospital, Nanjing Medical University
Jan 9, 2023